ADMA Biologics (ADMA) vs Relay Therapeutics (RLAY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Relay Therapeutics (RLAY) has outperformed ADMA Biologics (ADMA) over the past year, gaining 184.9% versus a loss of 29.3%. Over five years, ADMA leads with a +839.1% price change compared with -49.0% for RLAY. Relay Therapeutics is the larger company by market cap ($3.92 billion vs $2.32 billion), about 1.7 times the size.
ADMA Biologics converts more of its revenue into profit, with a net margin of 28.8% versus -1800.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | RLAY |
|---|---|---|
| Share price | $10.36 | $17.88 |
| Market cap | $2.32B | $3.92B |
| 1-day change | +0.29% | +2.70% |
| YTD return | -43.37% | +105.79% |
| 1-year return | -29.34% | +184.94% |
| 5-year return | +839.09% | -48.96% |
| P/E ratio (TTM) | 14.80 | — |
| Forward P/E | 10.98 | — |
| EPS (TTM) | $0.70 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $510.17M | $15.36M |
| Revenue growth (YoY) | +19.63% | +53.44% |
| Net income (latest FY) | $146.93M | $-276.48M |
| Gross margin | 57.39% | — |
| Operating margin | 37.53% | -1971.59% |
| Net margin | 28.80% | -1800.58% |
| 52-week high | $20.46 | $21.27 |
| 52-week low | $7.21 | $5.85 |
| Distance from 52-week high | -49.36% | -15.94% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +64.09% | +54.25% |
| Average volume | 2.66M | 2.80M |
| Shares outstanding | 223.98M | 219.14M |
| Employees | 640 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLAY has outperformed ADMA by 214.3 percentage points over the past year.
- ADMA Biologics is more profitable, keeping 28.8 cents of every revenue dollar as net income versus -1800.6 cents for Relay Therapeutics.
- Relay Therapeutics grew revenue faster in its latest fiscal year (+53.44% vs +19.63%).
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Relay Therapeutics
RLAY stock →Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 202 employees
ADMA vs RLAY FAQ
Which is bigger, ADMA Biologics or Relay Therapeutics?
Relay Therapeutics (RLAY) is larger, with a market capitalization of $3.92B compared with $2.32B for ADMA Biologics (ADMA).
Which stock has performed better over the past year, ADMA or RLAY?
RLAY returned +184.94% over the past 12 months, compared with -29.34% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Relay Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.